薬理学ガイド
薬理学、薬物機序、臨床応用などを網羅した詳細な教育記事。
Antimicrobials
Antimicrobial Pharmacology Principles
Antimicrobial pharmacology bridges drug mechanisms, pharmacokinetics, and microbial biology to guide rational antibiotic selection and dosing.
Beta-Lactam Antibiotics
Beta-lactam antibiotics inhibit bacterial cell wall synthesis by irreversibly binding penicillin-binding proteins, causing osmotic lysis.
Aminoglycosides Pharmacology
Aminoglycosides cause irreversible mistranslation of bacterial proteins and have concentration-dependent bactericidal activity, but require monitoring for nephrotoxicity and ototoxicity.
Fluoroquinolones Pharmacology
Fluoroquinolones inhibit bacterial DNA gyrase and topoisomerase IV, providing broad-spectrum bactericidal activity with concentration-dependent killing.
Macrolides and Ketolides
Macrolides inhibit bacterial protein synthesis at the 50S ribosomal subunit and are essential for atypical respiratory pathogens and sexually transmitted …
Tetracyclines and Glycylcyclines
Tetracyclines inhibit 30S ribosomal binding of aminoacyl-tRNA and have broad spectrum activity including intracellular pathogens and zoonotic infections.
Glycopeptide and Lipopeptide Antibiotics
Vancomycin and daptomycin target gram-positive bacteria by disrupting cell wall synthesis and membrane integrity, respectively, serving as critical agents against …
Sulfonamides and Trimethoprim
Sulfonamides and trimethoprim block sequential steps in bacterial folate synthesis, achieving synergistic bactericidal activity in combination.
Antifungal Agents
Antifungal drugs target unique fungal cell biology including ergosterol synthesis, cell membrane integrity, and glucan synthesis to treat systemic and …
Antiviral Agents Overview
Antiviral agents target virus-specific enzymes including viral polymerases, proteases, and entry mechanisms, exploiting differences from host cell machinery.
Antiretroviral Therapy
Antiretroviral therapy combines drugs targeting HIV reverse transcriptase, integrase, and protease to achieve viral suppression and immune reconstitution.
Antimalarial Drugs
Antimalarial drugs target specific life cycle stages of Plasmodium parasites using mechanisms ranging from heme crystallization inhibition to antifolate activity.
Antituberculosis Agents
Tuberculosis treatment requires prolonged multi-drug regimens to eliminate all bacterial populations and prevent resistance emergence.
Antibiotic Resistance Pharmacology
Antibiotic resistance emerges through genetic mechanisms including enzymatic inactivation, target modification, and efflux pumps that can be transmitted horizontally.
Anthelmintic and Antiprotozoal Drugs
Anthelmintic and antiprotozoal drugs target unique metabolic pathways of parasitic worms and protozoa, treating infections ranging from intestinal helminths to …
Antimicrobial Stewardship Pharmacology
Antimicrobial stewardship programs optimize antibiotic use to improve patient outcomes, reduce adverse effects, and slow the emergence of antibiotic resistance.
Cardiovascular Pharmacology
Cardiovascular Drug Targets
An overview of the molecular and cellular targets exploited by cardiovascular drugs, from ion channels and receptors to enzymes and …
Antihypertensive Drug Classes
A systematic review of the five major antihypertensive drug classes, their mechanisms, evidence base, and selection criteria.
Heart Failure Pharmacotherapy
Evidence-based pharmacotherapy for heart failure with reduced ejection fraction, covering the four pillars of guideline-directed medical therapy.
Antianginal Medications
Pharmacology of drugs used to prevent and treat angina pectoris, including nitrates, beta-blockers, calcium channel blockers, and newer agents.
Antiarrhythmic Drug Classes
The Vaughan-Williams classification of antiarrhythmic drugs, their electrophysiological mechanisms, and clinical applications.
Anticoagulation Therapy
A guide to anticoagulant pharmacology including heparins, warfarin, and direct oral anticoagulants, covering mechanisms, monitoring, and reversal.
Antiplatelet Drug Mechanisms
How antiplatelet drugs work at the molecular level, from aspirin's COX-1 inhibition to P2Y12 receptor antagonists and GP IIb/IIIa inhibitors.
Thrombolytic Agents
Pharmacology of fibrinolytic drugs used to dissolve acute thrombi in STEMI, ischemic stroke, and pulmonary embolism.
Lipid-Lowering Pharmacology
Comprehensive pharmacology of statins, ezetimibe, PCSK9 inhibitors, fibrates, and other agents that reduce cardiovascular risk through lipid modification.
Vasodilator Pharmacology
Mechanisms and clinical uses of arterial, venous, and mixed vasodilators in hypertensive emergencies, heart failure, and peripheral vascular disease.
Cardiac Glycosides
Pharmacology of digoxin and related cardiac glycosides, including mechanism of action, therapeutic monitoring, toxicity, and the role of digoxin-specific antibodies.
Beta-Blocker Cardiovascular Uses
A detailed guide to beta-adrenergic receptor antagonists in cardiovascular medicine, covering selectivity, indications, and agent-specific differences.
Calcium Channel Blocker Uses
Pharmacology and clinical applications of dihydropyridine and non-dihydropyridine calcium channel blockers across cardiovascular conditions.
RAAS System Pharmacology
The renin-angiotensin-aldosterone system and drugs that modulate it: ACE inhibitors, ARBs, direct renin inhibitors, MRAs, and ARNIs.
Pulmonary Arterial Hypertension Drugs
Pharmacotherapy for pulmonary arterial hypertension targeting the endothelin, nitric oxide, and prostacyclin pathways.
Peripheral Vascular Disease Treatment
Pharmacological management of peripheral arterial disease, including antiplatelet therapy, cilostazol, risk factor modification, and emerging treatments.
Cardiovascular Drug Interactions
Clinically significant drug interactions in cardiovascular pharmacotherapy, covering pharmacokinetic and pharmacodynamic mechanisms.
Novel Cardiovascular Therapies
Emerging and recently approved cardiovascular therapies including RNA-based drugs, gene therapy, cardiac myosin activators, and anti-inflammatory agents.
Clinical Trials
Clinical Trial Phases Overview
A complete overview of the four phases of clinical trials that every drug must pass through before and after reaching …
Phase I Trial Design
How Phase I trials establish drug safety in humans through dose-escalation designs and pharmacokinetic profiling.
Phase II Trial Design
Phase II trials provide the first evidence of drug efficacy and refine dosing through proof-of-concept and dose-ranging studies.
Phase III Confirmatory Trials
Phase III trials provide the pivotal evidence regulators require for drug approval through large-scale randomized controlled studies.
Phase IV Post-Marketing Studies
Phase IV studies monitor drug safety and effectiveness in real-world populations after regulatory approval.
Randomized Controlled Trials
Randomized controlled trials are the gold standard for establishing causal relationships between drug treatments and clinical outcomes.
Double-Blind Study Design
Double-blind designs prevent bias by concealing treatment assignments from both participants and investigators.
Placebo-Controlled Trials
Placebo-controlled trials isolate the true pharmacological effect of a drug from the psychological and physiological placebo response.
Adaptive Trial Designs
Adaptive trial designs allow pre-planned modifications based on accumulating data, improving efficiency without compromising statistical rigor.
Bioequivalence Studies
Bioequivalence studies demonstrate that a generic drug delivers the same active ingredient to the bloodstream as the brand-name reference product.
Endpoint Selection in Clinical Trials
Choosing the right primary endpoint determines whether a clinical trial can convincingly demonstrate a drug's therapeutic value.
Statistical Analysis in Drug Trials
Statistical methods in drug trials determine whether observed treatment differences reflect genuine drug effects or random variation.
Informed Consent Process
Informed consent ensures that clinical trial participants understand the risks, benefits, and alternatives before voluntarily agreeing to participate.
Adverse Event Reporting
Adverse event reporting systems capture, classify, and communicate safety information throughout clinical drug development.
Good Clinical Practice
Good Clinical Practice (GCP) is the international quality standard for designing, conducting, recording, and reporting clinical trials.
Regulatory Submission Process
The regulatory submission process transforms clinical trial data into a formal application for marketing authorization of a new drug.
Orphan Drug Development
Orphan drug programs provide regulatory and financial incentives to develop treatments for rare diseases affecting small patient populations.
Pediatric Drug Development
Pediatric drug development addresses the unique pharmacological, ethical, and regulatory challenges of testing medicines in children.
Drug Classes
Beta-Blockers: A Complete Guide
Beta-blockers reduce heart rate and blood pressure by blocking beta-adrenergic receptors. They remain foundational drugs in cardiology, used for hypertension, …
ACE Inhibitors and ARBs
ACE inhibitors and angiotensin receptor blockers target the renin-angiotensin-aldosterone system to lower blood pressure, protect the kidneys, and improve survival …
Calcium Channel Blockers
Calcium channel blockers inhibit L-type calcium channels in cardiac and vascular smooth muscle. The dihydropyridine and non-dihydropyridine subclasses have distinct …
Statins and Lipid-Lowering Agents
Statins are the cornerstone of lipid-lowering therapy, reducing cardiovascular events by inhibiting HMG-CoA reductase. Newer agents like PCSK9 inhibitors offer …
Proton Pump Inhibitors
Proton pump inhibitors irreversibly block the gastric H+/K+-ATPase, providing the most potent suppression of acid secretion available. They are essential …
SSRIs and Serotonin Modulators
Selective serotonin reuptake inhibitors are the most prescribed antidepressants worldwide. Newer serotonin modulators expand options for treatment-resistant depression and anxiety …
Benzodiazepines and Anxiolytics
Benzodiazepines enhance GABAergic inhibition for rapid anxiolytic, sedative, and anticonvulsant effects. Their dependence potential has shifted prescribing toward safer long-term …
Opioid Analgesics
Opioids activate mu, kappa, and delta receptors to produce powerful analgesia. Understanding their pharmacology is essential for effective pain management …
NSAIDs: Mechanisms and Risks
NSAIDs inhibit cyclooxygenase enzymes to reduce pain, inflammation, and fever. Their widespread OTC availability masks significant gastrointestinal, cardiovascular, and renal …
Anticoagulants: Warfarin to DOACs
Anticoagulants prevent thrombus formation by targeting different points in the coagulation cascade. The shift from warfarin to direct oral anticoagulants …
Diuretics: Types and Uses
Diuretics increase renal sodium and water excretion by acting at different nephron segments. Thiazides, loop diuretics, and potassium-sparing agents each …
Corticosteroids in Medicine
Corticosteroids are among the most potent anti-inflammatory and immunosuppressive drugs available. Their broad effects on nearly every organ system demand …
Antiepileptic Drugs
Antiepileptic drugs control seizures through diverse mechanisms including sodium channel blockade, GABA enhancement, and calcium current modulation. Drug selection depends …
Antipsychotics: Typical vs Atypical
Antipsychotics treat schizophrenia and other psychotic disorders by modulating dopamine pathways. First-generation agents primarily block D2 receptors, while second-generation agents …
Aminoglycoside Antibiotics
Aminoglycosides provide concentration-dependent bactericidal activity against gram-negative organisms. Their narrow therapeutic index requires therapeutic drug monitoring to balance efficacy against …
Fluoroquinolone Antibiotics
Fluoroquinolones inhibit bacterial DNA gyrase and topoisomerase IV, providing broad-spectrum coverage. FDA black box warnings for tendon rupture, neuropathy, and …
Insulin and Oral Hypoglycemics
Diabetes pharmacotherapy spans injectable insulins and multiple oral drug classes targeting different pathophysiological mechanisms. Modern treatment emphasizes individualized glycemic targets, …
Immunosuppressants Overview
Immunosuppressants prevent transplant rejection and control autoimmune diseases by targeting different stages of immune cell activation. Balancing efficacy against infection …
Monoclonal Antibody Therapeutics
Monoclonal antibodies represent the fastest-growing segment of the pharmaceutical market, targeting specific proteins in oncology, autoimmune diseases, and beyond. Understanding …
Antihistamines: H1 and H2 Blockers
Antihistamines block histamine receptors to treat allergic conditions (H1) and acid-related disorders (H2). First- and second-generation H1 blockers differ dramatically …
Drug Development
Drug Discovery Pipeline
Overview of the drug discovery process from initial concept through target selection, hit identification, lead optimization, and candidate selection.
Target Identification and Validation
Methods for identifying and validating drug targets -- from genomics and proteomics to CRISPR screens, Mendelian randomization, and clinical biomarkers.
Lead Optimization Process
How medicinal chemists transform initial hits into drug candidates by optimizing potency, selectivity, ADME properties, and safety profiles.
Preclinical Drug Development
GLP toxicology studies, ADME characterization, formulation development, and manufacturing scale-up required before first-in-human clinical trials.
IND Application Process
How to prepare and submit an Investigational New Drug application to the FDA -- content requirements, review timeline, and common …
Drug Formulation Science
How drug substances are formulated into dosage forms -- solubility enhancement, excipient selection, controlled release, and biologic formulation challenges.
Regulatory Approval Pathways
FDA approval pathways including standard NDA, accelerated approval, breakthrough therapy, priority review, and international regulatory frameworks.
Post-Marketing Drug Development
Phase IV studies, pharmacovigilance, label expansion, real-world evidence, and lifecycle management strategies after initial drug approval.
Immunopharmacology
Immune System Pharmacology Basics
Foundation concepts linking innate and adaptive immunity to pharmacological targets, from cytokine signaling to lymphocyte activation pathways.
Immunosuppressive Drug Mechanisms
Comprehensive overview of immunosuppressive drug classes, their molecular targets, and how they achieve selective immune suppression.
Calcineurin Inhibitor Pharmacology
Deep dive into cyclosporine and tacrolimus -- binding partners, calcineurin-NFAT inhibition, pharmacokinetics, nephrotoxicity, and drug interactions.
mTOR Inhibitor Pharmacology
How sirolimus and everolimus block mTOR-driven cell cycle progression, their role in transplantation, and dual immunosuppressive-antiproliferative activity.
Anti-TNF Therapy
TNF-alpha biology, five approved anti-TNF biologics, their structural differences, indications across autoimmune diseases, and safety considerations.
Interleukin Modulators
Pharmacology of drugs targeting interleukins including IL-1, IL-6, IL-17, IL-23, IL-4/13, and IL-5 -- mechanisms, indications, and clinical outcomes.
B-Cell Targeted Therapies
Anti-CD20 antibodies, BAFF inhibitors, BTK inhibitors, and plasma cell-targeting agents -- how B-cell depletion and modulation treat autoimmune disease.
Complement Inhibitors
Pharmacology of complement-targeting therapies including C5 inhibitors, C3 inhibitors, and factor-targeted agents for PNH, aHUS, and other diseases.
Vaccine Pharmacology
Vaccine types, adjuvant mechanisms, immune response kinetics, mRNA platform technology, and pharmacological principles underlying vaccination.
Allergy Pharmacotherapy
Pharmacology of allergic disease treatment from antihistamines and mast cell stabilizers to epinephrine, corticosteroids, and allergen immunotherapy.
Autoimmune Disease Treatment
Pharmacological strategies for autoimmune diseases -- from conventional DMARDs to biologics and targeted synthetic agents across major disease categories.
Transplant Immunopharmacology
Induction, maintenance, and rejection therapy in organ transplantation -- drug regimens, monitoring strategies, and long-term immunosuppression management.
Drug Interactions
CYP3A4 Interactions
CYP3A4 metabolizes over 50% of clinically used drugs. Understanding its inhibitors and inducers is essential for predicting and preventing dangerous …
CYP2D6 Interactions
CYP2D6 metabolizes 25% of drugs including many antidepressants and opioids. Genetic polymorphisms add another layer of complexity to CYP2D6 drug …
CYP2C19 Interactions
CYP2C19 metabolizes proton pump inhibitors, clopidogrel, and several antidepressants. Genetic variants significantly alter drug response across ethnic populations.
Warfarin Drug Interactions
Warfarin has one of the longest lists of drug interactions of any medication. Its narrow therapeutic index makes even modest …
Serotonin Syndrome Risk
Serotonin syndrome is a potentially fatal condition caused by excessive serotonergic activity, most often from drug combinations. Recognizing the precipitants …
QT Prolongation Drug Combinations
Many common drugs prolong the QT interval. Combining them increases the risk of torsades de pointes, a potentially fatal ventricular …
NSAID Interaction Risks
NSAIDs interact with antihypertensives, anticoagulants, and nephrotoxic drugs through prostaglandin inhibition. These interactions are among the most common in clinical …
Statin Drug Interactions
Statin interactions primarily involve CYP3A4 and OATP1B1 transporter inhibition, raising statin plasma levels and the risk of myopathy and rhabdomyolysis.
Immunosuppressant Interactions
Transplant immunosuppressants have narrow therapeutic indices and complex metabolic profiles. Drug interactions can cause graft rejection or life-threatening toxicity.
Antibiotic Drug Interactions
Antibiotics interact with drugs through CYP inhibition, chelation, gut flora disruption, and QT prolongation. These interactions affect nearly every medical …
Antiepileptic Drug Interactions
Older antiepileptic drugs are potent enzyme inducers that affect contraceptives, anticoagulants, and immunosuppressants. Newer agents have fewer but still relevant …
Opioid Interaction Dangers
Opioid interactions with benzodiazepines, serotonergic drugs, and CYP inhibitors cause respiratory depression, serotonin syndrome, and overdose deaths. Understanding these risks …
Food-Drug Interactions
Foods can alter drug absorption, metabolism, and excretion through chelation, enzyme modulation, and pH changes. Grapefruit, dairy, and high-fat meals …
Alcohol-Drug Interactions
Alcohol interacts with drugs through CNS depression, CYP2E1 modulation, acetaldehyde accumulation, and GI effects. Both acute and chronic alcohol use …
Herbal-Drug Interactions
Herbal supplements are widely used but poorly regulated. St. John's wort, ginkgo, garlic, and many others cause clinically significant drug …
P-glycoprotein Mediated Interactions
P-glycoprotein is a drug efflux transporter that limits oral absorption and protects the brain. Inhibiting or inducing P-gp changes the …
Drug Interactions in Polypharmacy
Polypharmacy in elderly patients creates exponentially complex interaction networks. Systematic deprescribing and prioritization strategies can reduce adverse drug events by …
Pharmacogenomics and Drug Interactions
Pharmacogenomics reveals how genetic variants in drug-metabolizing enzymes, transporters, and targets convert standard doses into toxic or subtherapeutic exposures. Testing …
Mechanisms of Action
How Receptor Agonists Work
Learn how agonist drugs bind to receptors and activate downstream signaling cascades.
Enzyme Inhibition Mechanisms
Explore how drugs block enzyme activity to alter biochemical pathways.
Ion Channel Modulators
Understand how drugs modulate ion channels to control cellular excitability.
G-Protein Coupled Receptor Signaling
Discover how GPCRs transduce extracellular signals through G-protein cascades.
Nuclear Receptor Activation
Learn how lipophilic drugs activate nuclear receptors to regulate gene transcription.
Allosteric Modulation
Explore how drugs at allosteric sites fine-tune receptor activity without competing at the active site.
Irreversible vs Reversible Binding
Compare how reversible and irreversible drug-target interactions differ in duration and clinical impact.
Competitive vs Non-Competitive Inhibition
Understand the kinetic and clinical differences between competitive and non-competitive drug inhibition.
Prodrug Activation Mechanisms
Learn how inactive prodrugs are converted to active metabolites in the body.
Receptor Desensitization and Tolerance
Understand why prolonged drug exposure leads to diminished receptor responsiveness.
Signal Amplification in Drug Action
Discover how signal amplification cascades allow small drug doses to produce large biological effects.
Partial Agonists and Functional Selectivity
Learn how partial agonists produce submaximal responses and exhibit pathway-selective signaling.
Inverse Agonism Explained
Understand how inverse agonists reduce constitutive receptor activity below basal levels.
Biased Agonism and Signaling
Explore how biased agonists selectively activate specific downstream pathways from a single receptor.
Enzyme Induction and Drug Metabolism
Learn how drugs induce metabolic enzymes, altering their own or other drugs' clearance.
Transporter-Mediated Drug Action
Discover how membrane transporters serve as drug targets and influence drug disposition.
Antibody-Based Drug Mechanisms
Understand how monoclonal antibodies exert therapeutic effects through diverse mechanisms.
Antisense and RNA-Based Mechanisms
Explore how antisense oligonucleotides, siRNA, and mRNA therapeutics modulate gene expression.
Epigenetic Drug Targets
Learn how drugs targeting epigenetic modifications reprogram gene expression without altering DNA sequence.
Multi-Target Drug Mechanisms
Understand how drugs acting on multiple targets achieve synergistic therapeutic effects.
Neuropharmacology
Neurotransmitter Systems Overview
A survey of the major neurotransmitter systems, their signaling mechanisms, and their relevance to pharmacological intervention.
Dopaminergic Pharmacology
How dopamine pathways regulate movement, reward, and cognition, and how drugs modulate dopaminergic transmission.
Serotonergic Pharmacology
The serotonin system's role in mood, sleep, and appetite, and how SSRIs, triptans, and psychedelics interact with 5-HT receptors.
GABAergic Pharmacology
GABA as the brain's primary inhibitory neurotransmitter, GABA-A and GABA-B receptor pharmacology, and drugs that enhance inhibition.
Glutamatergic Pharmacology
Glutamate as the major excitatory neurotransmitter, NMDA and AMPA receptor function, and drugs targeting excitatory transmission.
Cholinergic Pharmacology
Acetylcholine signaling through nicotinic and muscarinic receptors, and drugs that modify cholinergic transmission.
Noradrenergic Pharmacology
Norepinephrine pathways in the CNS and periphery, adrenergic receptor subtypes, and drugs modulating noradrenergic transmission.
Opioid Receptor Pharmacology
Opioid receptor types, endogenous opioid peptides, and the pharmacology of opioid agonists, antagonists, and partial agonists.
Cannabinoid Pharmacology
The endocannabinoid system, CB1 and CB2 receptors, and the pharmacology of THC, CBD, and synthetic cannabinoids.
Antidepressant Mechanisms
How different classes of antidepressants work, from monoamine reuptake inhibition to glutamatergic and neuroplasticity-based mechanisms.
Antipsychotic Drug Actions
How typical and atypical antipsychotics differ in receptor binding profiles, efficacy, and side effect patterns.
Anxiolytic Mechanisms
The neurobiology of anxiety and how benzodiazepines, buspirone, SSRIs, and emerging agents reduce pathological anxiety.
Pharmacology of Epilepsy
Antiseizure drug mechanisms grouped by sodium channel blockade, GABAergic enhancement, and synaptic vesicle protein binding.
Pharmacology of Parkinson's Disease
Drug strategies to restore dopaminergic-cholinergic balance in Parkinson's disease, from levodopa to MAO-B inhibitors and beyond.
Pharmacology of Alzheimer's Disease
Current and emerging drug strategies for Alzheimer's disease, from cholinesterase inhibitors to anti-amyloid monoclonal antibodies.
Pain Pharmacology
Pain pathway pharmacology from peripheral nociception to central modulation, covering NSAIDs, opioids, and adjuvant analgesics.
General Anesthetics
Inhalational and intravenous general anesthetics, their molecular targets, and the components of the anesthetic state.
Local Anesthetics
How local anesthetics block sodium channels to produce reversible nerve conduction blockade, and clinical considerations for their use.
Oncology Pharmacology
Cancer Cell Biology and Drug Targets
Cancer arises from genetic alterations that dysregulate cell proliferation, survival, and death, creating exploitable drug targets across multiple pathways.
Alkylating Agents Pharmacology
Alkylating agents form covalent bonds with DNA, crosslinking strands and causing cell death regardless of cell cycle phase.
Antimetabolites in Cancer Therapy
Antimetabolites are structural analogs of natural nucleotides and folate cofactors that disrupt DNA synthesis and cellular metabolism in cancer cells.
Topoisomerase Inhibitors
Topoisomerase inhibitors trap enzyme-DNA cleavage complexes, causing lethal DNA strand breaks in rapidly dividing cancer cells.
Mitotic Inhibitors: Taxanes and Vinca Alkaloids
Taxanes and vinca alkaloids disrupt microtubule dynamics through opposing mechanisms, both causing mitotic arrest and apoptosis in cancer cells.
Platinum-Based Chemotherapy
Platinum compounds form DNA adducts that crosslink DNA strands, causing apoptosis in a broad range of solid tumors.
Tyrosine Kinase Inhibitors
Tyrosine kinase inhibitors selectively block oncogenic kinase signaling, revolutionizing targeted cancer therapy with improved efficacy and tolerability.
Monoclonal Antibodies in Oncology
Therapeutic monoclonal antibodies target tumor-associated antigens to block growth signals, recruit immune effectors, and deliver cytotoxic payloads.
Immune Checkpoint Inhibitors
Immune checkpoint inhibitors release T-cell suppression by blocking PD-1, PD-L1, or CTLA-4, unleashing durable antitumor immunity.
Hormonal Therapy in Cancer
Hormonal therapies exploit hormone receptor dependence in breast and prostate cancers by reducing hormone levels or blocking receptor signaling.
Targeted Therapy and Signal Transduction
Targeted therapies inhibit specific oncogenic signaling pathways including RAS-MAPK, PI3K-AKT-mTOR, and others that drive cancer cell survival.
CAR-T Cell Therapy
CAR-T cell therapy engineers patient T cells with chimeric antigen receptors that recognize and kill tumor cells with high specificity.
Angiogenesis Inhibitors
Angiogenesis inhibitors block tumor blood vessel formation by targeting VEGF signaling, starving tumors of oxygen and nutrients.
Chemotherapy Resistance Mechanisms
Cancer cells develop resistance through drug efflux, target alterations, enhanced DNA repair, and antiapoptotic pathway activation.
Supportive Care Drugs in Oncology
Supportive care drugs manage chemotherapy toxicities including nausea, myelosuppression, pain, and metabolic emergencies to maintain treatment tolerability.
Combination Chemotherapy Principles
Combining drugs with different mechanisms, non-overlapping toxicities, and independent resistance pathways maximizes tumor kill while preserving patient tolerance.
Pharmacokinetics
Understanding Drug Absorption
How drugs cross biological membranes to enter the bloodstream, and the factors that determine absorption rate and extent.
Drug Distribution in the Body
How drugs travel from the bloodstream into tissues, and the factors that determine where drugs accumulate in the body.
Hepatic Drug Metabolism
How the liver transforms drugs through Phase I and Phase II reactions, and the role of cytochrome P450 enzymes.
Renal Drug Excretion
How the kidneys eliminate drugs through glomerular filtration, tubular secretion, and reabsorption.
Bioavailability and First-Pass Effect
Why oral drugs often deliver less active compound than the administered dose, and how first-pass metabolism reduces bioavailability.
Drug Half-Life and Dosing
How elimination half-life determines dosing frequency, time to steady state, and drug accumulation during chronic therapy.
Steady-State Pharmacokinetics
The equilibrium between drug input and elimination during chronic therapy, and how it determines average drug levels.
Volume of Distribution Explained
What volume of distribution really means, why some drugs have Vd values exceeding total body water, and its clinical implications.
Clearance and Elimination
How the body removes drugs through hepatic and renal clearance, and the relationship between clearance and steady-state levels.
Non-Linear Pharmacokinetics
When pharmacokinetics deviate from first-order behavior — saturable metabolism, dose-dependent kinetics, and Michaelis-Menten elimination.
Drug-Drug PK Interactions
How co-administered drugs alter each other's absorption, distribution, metabolism, and excretion through pharmacokinetic mechanisms.
PK of Special Populations
How pharmacokinetics differ in neonates, elderly patients, obese individuals, and critically ill patients.
Pediatric Pharmacokinetics
How drug absorption, distribution, metabolism, and excretion change from birth through adolescence, and implications for pediatric dosing.
Geriatric Pharmacokinetics
How aging affects drug processing, why elderly patients are more susceptible to adverse drug reactions, and principles of geriatric dosing.
PK in Pregnancy
How pregnancy-related physiological changes alter drug pharmacokinetics and challenge dosing decisions for mother and fetus.
PK in Renal Impairment
How kidney disease affects drug elimination and dosing, and practical approaches to dose adjustment in renal impairment.
PK in Hepatic Impairment
How liver disease affects drug metabolism and dosing, and why hepatic dose adjustments are less precise than renal adjustments.
Population Pharmacokinetics
How population PK models identify sources of variability in drug response across patient groups and inform individualized dosing.
Pharmacokinetic Modeling
The mathematical frameworks used to describe drug concentration-time profiles, from simple compartmental models to physiologically based models.
Therapeutic Drug Monitoring
When and how to measure drug levels to optimize therapy, including sampling strategies, target ranges, and clinical decision-making.
Toxicology
Drug-Induced Liver Injury
Drug-induced liver injury (DILI) is a leading cause of acute liver failure. Understanding its mechanisms, risk factors, and early detection …
Nephrotoxicity of Common Drugs
Many widely prescribed drugs can damage the kidneys. Understanding nephrotoxic mechanisms and monitoring strategies helps preserve renal function.
Cardiotoxicity: Mechanisms and Prevention
Drug-induced cardiotoxicity can manifest as arrhythmias, cardiomyopathy, or heart failure. Recognizing mechanisms enables safer prescribing.
Neurotoxicity in Pharmacotherapy
Drug-induced neurotoxicity ranges from peripheral neuropathy to seizures and encephalopathy. Awareness of risk agents and early symptoms is critical.
Drug Overdose Management
Effective drug overdose management follows a systematic approach: stabilize, decontaminate, administer specific antidotes, and provide supportive care.
Therapeutic Index and Safety
The therapeutic index quantifies the margin between a drug's effective and toxic doses. Narrow therapeutic index drugs require careful dosing …
Dose-Response Relationships
Dose-response relationships describe how drug effects change with increasing concentration. Understanding these curves is fundamental to pharmacology and toxicology.
Idiosyncratic Drug Reactions
Idiosyncratic drug reactions are unpredictable, dose-independent adverse effects with immune or metabolic origins. They are a major challenge in drug …
Drug Allergy vs Side Effects
Distinguishing true drug allergy from common side effects is clinically essential. Misclassification leads to unnecessary drug avoidance and suboptimal treatment.
Teratogenicity and Pregnancy Categories
Certain drugs cause birth defects when used during pregnancy. Understanding teratogenic risk periods, mechanisms, and classification systems guides safer prescribing.
Pharmacogenomics and Adverse Reactions
Genetic variation in drug-metabolizing enzymes, transporters, and immune molecules explains much inter-individual variability in adverse drug reactions.
Drug-Induced QT Prolongation
Drug-induced QT prolongation increases the risk of torsades de pointes, a potentially fatal arrhythmia. Hundreds of drugs affect the QT …
Hepatotoxicity Biomarkers
Traditional liver enzymes remain the standard for detecting hepatotoxicity, but emerging biomarkers offer earlier detection and better prognostic accuracy.
Drug-Induced Kidney Injury Markers
Serum creatinine detects kidney injury late. Novel urinary biomarkers like KIM-1, NGAL, and clusterin enable earlier detection of drug-induced nephrotoxicity.
Antidote Pharmacology
Antidotes reverse drug toxicity through specific mechanisms: receptor antagonism, metabolic rescue, chelation, or antibody neutralization. Timely administration saves lives.
Drug Safety Monitoring Systems
Post-marketing pharmacovigilance systems detect rare adverse drug reactions that clinical trials miss. Reporting, signal detection, and regulatory action protect public …